Changes in physical examination, echocardiography and functional status 6 months after initiation of sacubitril/valsartan treatment, n=18
| Variable | Mean±SD Baseline | Mean±SD 6 months | P value |
| General | |||
| NYHA class (n, %) | 0.112 | ||
| II | 13 (72%) | 15 (83%) | |
| III–IV | 5 (28%) | 3 (17%) | |
| Systolic blood pressure (mm Hg) | 106±10 | 106±14 | 0.960 |
| Weight (kg) | 80±18 | 79±18 | 0.187 |
| 6 min walking distance (m) | 564±104 | 600±72 | 0.011* |
| Echocardiography: | |||
| Global RV function, (n, %) | 0.157 | ||
| Mildly reduced | 4 (22%) | 5 (28%) | |
| Moderately reduced | 10 (56%) | 10 (56%) | |
| Severely reduced | 4 (22%) | 3 (16%) | |
| TAPSE (mm) | 12±2 | 11±2 | 0.211 |
| RV FAC (%) | 19±7 | 22±7 | <0.001* |
| RV GLS (%) | −11±3 | −13±2 | 0.014* |
| RVEDD (mm) | 59±9 | 58±8 | 0.067 |
| Tricuspid valve regurgitation (n, %) | 1.000 | ||
| Grade I–II | 15 (88%) | 15 (88%) | |
| Grade III–IV | 2 (12%) | 2 (12%) | |
| LV GLS (%) | −16±4 | −18±5 | 0.110 |
| MAPSE (mm) | 18±5 | 18±3 | 0.663 |
| Exercise testing | |||
| Exercise capacity (W) | 129±50 | 132±47 | 0.402 |
| Exercise capacity (%) | 79±17 | 81±17 | 0.575 |
| VO2max (ml/min/kg) | 18±5 | 18±4 | 0.886 |
| % of predicted VO2max achieved | 59±15 | 58±13 | 0.746 |
| % of predicted heart rate achieved | 77±13 | 78±14 | 0.717 |
| Heart rate reserve (bpm) | 66±24 | 65±26 | 0.795 |
| RER | 1.20±0.09 | 1.17±0.07 | 0.367 |
*Statistically significant.
bpm, beats per minute; FAC, fractional area change; GLS, global longitudinal strain; LV, (subpulmonary) left ventricle; MAPSE, mitral annular plane systolic excursion; NYHA, New York Heart Association functional classification; RER, respiratory exchange ratio; RV, (systemic) right ventricle; RVEDD, (systemic) right ventricular end diastolic diameter (basal measurement); ; TAPSE, tricuspid annular plane systolic excursion.